Antibody recognition of aberrant glycosylation on the surface of cancer cells

Current Opinion in Structural Biology

Volumn 44, Issue , 2017, Pages 1-8

  Soliman, Caroline ^a   Yuriev, Elizabeth ^b   Ramsland, Paul A ^a,b,c,d  

^a RMIT UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d BURNET INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GANGLIOSIDE; TUMOR ANTIGEN; TUMOR ASSOCIATED CARBOHYDRATE ANTIGEN; UNCLASSIFIED DRUG; ANTIBODY; POLYSACCHARIDE;

ANTIGEN BINDING; ANTIGEN RECOGNITION; BIOLOGICAL ACTIVITY; BLOOD GROUP ABO SYSTEM; CANCER CELL; CELL MEMBRANE; CELL SURFACE; CRYSTAL STRUCTURE; GLYCOSYLATION; HUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; EPITOPES; GLYCOSYLATION; HUMANS; NEOPLASMS; POLYSACCHARIDES;

EID: 84993972005     PISSN: 0959440X     EISSN: 1879033X     Source Type: Journal    
DOI: 10.1016/j.sbi.2016.10.009     Document Type: Review

References (49)

1. 1 Kobata, A., Amano, J., Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours. Immunol Cell Biol 83 (2005), 429–439.
2. 2 Ghazarian, H., Idoni, B., Oppenheimer, S.B., A glycobiology review: carbohydrates, lectins and implications in cancer therapeutics. Acta Histochem 113 (2011), 236–247.
3. 3• Dingjan, T., Spendlove, I., Durrant, L.G., Scott, A.M., Yuriev, E., Ramsland, P.A., Structural biology of antibody recognition of carbohydrate epitopes and potential uses for targeted cancer immunotherapies. Mol Immunol 67 (2015), 75–88 A detailed review focusing on the conformational properties of Lewis blood-group related carbohydrates bound to antibodies and lectins. Also discussed, are the implications of these structural data for the design of improved antibodies and vaccines as targeted cancer immunotherapies.
4. 4 Freire, T., Osinaga, E., The sweet side of tumor immunotherapy. Immunotherapy 4 (2012), 719–734.
5. 5• Steplewski, Z., Thurin, M., Kieber-Emmons, T., Antibodies: at the nexus of antigens and cancer vaccines. J Infect Dis 212:Suppl. 1 (2015), S59–S66 Examines the complex biological activities of tumor-targeting antibodies, particularly those recognizing carbohydrate antigens and details how structure–function studies are leading to new opportunities in vaccines for cancer.
6. 6 Scott, A.M., Allison, J.P., Wolchok, J.D., Monoclonal antibodies in cancer therapy. Cancer Immun, 12, 2012, 14.
7. 7 Redman, J.M., Hill, E.M., AlDeghaither, D., Weiner, L.M., Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol 67 (2015), 28–45.
8. 8 Durrant, L.G., Noble, P., Spendlove, I., Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy. Clin Exp Immunol 167 (2012), 206–215.
9. 9• Vankemmelbeke, M., Chua, J.X., Durrant, L.G., Cancer cell associated glycans as targets for immunotherapy. Oncoimmunology, 5, 2016, e1061177 A focused mini-review on the complex biological activities of glycolipid-binding antibodies. Mechanisms of direct antibody action including oncosis are discussed.
10. 10 Agostino, M., Farrugia, W., Sandrin, M.S., Scott, A.M., Yuriev, E., Ramsland, P.A., Chapter 9 — structural glycobiology of antibody recognition in xenotransplantation and cancer immunotherapy. Kosma, P., Muller-Loennies, S., (eds.) Anticarbohydrate Antibodies, 2012, Springer, 203–228.
11. 11 Dhillon, S., Dinutuximab: first global approval. Drugs 75 (2015), 923–927.
12. 12•• Horwacik, I., Golik, P., Grudnik, P., Kolinski, M., Zdzalik, M., Rokita, H., Dubin, G., Structural basis of GD2 ganglioside and mimetic peptide recognition by 14G2a antibody. Mol Cell Proteomics 14 (2015), 2577–2590 The first crystal structure of a ganglioside-binding antibody in complex with its target glycan headgroup. Structures of Fab-peptide complexes were also determined, but differences between carbohydrate and peptide recognition indicate functional and not structural mimicry by these peptides.
13. 13 Sterner, E., Flanagan, N., Gildersleeve, J.C., Perspectives on anti-glycan antibodies gleaned from development of a community resource database. ACS Chem Biol 11 (2016), 1773–1783.
14. 14 Adler, M.J., Dimitrov, D.S., Therapeutic antibodies against cancer. Hematol Oncol Clin North Am 26 (2012), 447–481.
15. 15 Ramsland, P.A., Farrugia, W., Yuriev, E., Edmundson, A.B., Sandrin, M.S., Evidence for structurally conserved recognition of the major carbohydrate xenoantigen by natural antibodies. Cell Mol Biol 49 (2003), 307–317.
16. 16•• Haji-Ghassemi, O., Blackler, R.J., Martin Young, N., Evans, S.V., Antibody recognition of carbohydrate epitopes. Glycobiology 25 (2015), 920–952 A comprehensive review of all known structures of carbohydrate-antibodies. The text is conveniently divided into disease areas with a major emphasis on infection (e.g. HIV and bacteria) and cancer, but many useful details of other carbohydrate-binding antibodies and the target glycans are provided.
17. 17 Dingjan, T., Agostino, M., Ramsland, P.A., Yuriev, E., Antibody-carbohydrate recognition from docked ensembles using the automap procedure. Methods Mol Biol 1331 (2015), 41–55.
18. 18 Yuriev, E., Farrugia, W., Scott, A.M., Ramsland, P.A., Three-dimensional structures of carbohydrate determinants of Lewis system antigens: implications for effective antibody targeting of cancer. Immunol Cell Biol 83 (2005), 709–717.
19. 19 Cazet, A., Julien, S., Bobowski, M., Burchell, J., Delannoy, P., Tumour-associated carbohydrate antigens in breast cancer. Breast Cancer Res, 12, 2010, 204.
20. 20 Brooks, C.L., Schietinger, A., Borisova, S.N., Kufer, P., Okon, M., Hirama, T., Mackenzie, C.R., Wang, L.X., Schreiber, H., Evans, S.V., Antibody recognition of a unique tumor-specific glycopeptide antigen. Proc Natl Acad Sci U S A 107 (2010), 10056–10061.
21. 21 Tessier, M.B., Grant, O.C., Heimburg-Molinaro, J., Smith, D., Jadey, S., Gulick, A.M., Glushka, J., Deutscher, S.L., Rittenhouse-Olson, K., Woods, R.J., Computational screening of the human TF-glycome provides a structural definition for the specificity of anti-tumor antibody JAA-F11. PLoS One, 8, 2013, e54874.
22. 22 Audfray, A., Beldjoudi, M., Breiman, A., Hurbin, A., Boos, I., Unverzagt, C., Bouras, M., Lantuejoul, S., Coll, J.L., Varrot, A., et al. A recombinant fungal lectin for labeling truncated glycans on human cancer cells. PLoS One, 10, 2015, e0128190.
23. 23 Luo, M., Velikovsky, C.A., Yang, X., Siddiqui, M.A., Hong, X., Barchi, J.J. Jr., Gildersleeve, J.C., Pancer, Z., Mariuzza, R.A., Recognition of the Thomsen-Friedenreich pancarcinoma carbohydrate antigen by a lamprey variable lymphocyte receptor. J Biol Chem 288 (2013), 23597–23606.
24. 24 Slovin, S.F., Keding, S.J., Ragupathi, G., Carbohydrate vaccines as immunotherapy for cancer. Immunol Cell Biol 83 (2005), 418–428.
25. 25 Yamazaki, Y., Sezukuri, K., Takada, J., Kimura, S., Ohmae, M., A novel chemoenzymatic synthesis of sulfated type 2 tumor-associated carbohydrate antigens via transglycosylation of sulfated Lewis X oxazoline catalyzed by keratanase II. Chembiochem 17 (2016), 1879–1886.
26. 26 Jeffrey, P.D., Bajorath, J., Chang, C.Y., Yelton, D., Hellstrom, I., Hellstrom, K.E., Sheriff, S., The X-ray structure of an anti-tumour antibody in complex with antigen. Nat Struct Biol 2 (1995), 466–471.
27. 27 Ramsland, P.A., Farrugia, W., Bradford, T.M., Hogarth, P.M., Scott, A.M., Structural convergence of antibody binding of carbohydrate determinants in Lewis Y tumor antigens. J Mol Biol 340 (2004), 809–818.
28. 28 van Roon, A.M., Pannu, N.S., de Vrind, J.P., van der Marel, G.A., van Boom, J.H., Hokke, C.H., Deelder, A.M., Abrahams, J.P., Structure of an anti-Lewis X Fab fragment in complex with its Lewis X antigen. Structure 12 (2004), 1227–1236.
29. 29 Reynolds, M., Fuchs, A., Lindhorst, T.K., Perez, S., The hydration features of carbohydrate determinants of Lewis antigens. Mol Simul 34 (2008), 447–460.
30. 30 Battistel, M.D., Azurmendi, H.F., Frank, M., Freedberg, D.I., Uncovering nonconventional and conventional hydrogen bonds in oligosaccharides through NMR experiments and molecular modeling: application to sialyl Lewis-X. J Am Chem Soc 137 (2015), 13444–13447.
31. 31 Jackson, T.A., Robertson, V., Auzanneau, F.I., Evidence for two populated conformations for the dimeric Le(x) and Le(a)Le(x) tumor-associated carbohydrate antigens. J Med Chem 57 (2014), 817–827.
32. x can occur in solution and upon binding. These novel conformational properties of Lewis glycans should now be considered in future antibody development and vaccine design projects.
33. 33 Fujita, A., Cheng, J., Hirakawa, M., Furukawa, K., Kusunoki, S., Fujimoto, T., Gangliosides GM1 and GM3 in the living cell membrane form clusters susceptible to cholesterol depletion and chilling. Mol Biol Cell 18 (2007), 2112–2122.
34. 34• Krengel, U., Bousquet, P.A., Molecular recognition of gangliosides and their potential for cancer immunotherapies. Front Immunol, 5, 2014, 325 Review of molecular properties and recognition of gangliosides by pathogen proteins and immune system proteins including antibodies. Antibody targeting of gangliosides for cancer immunotherapy is discussed.
35. 35 Ahmed, M., Goldgur, Y., Hu, J., Guo, H.F., Cheung, N.K., In silico driven redesign of a clinically relevant antibody for the treatment of GD2 positive tumors. PLoS One, 8, 2013, e63359.
36. 36 Pichla, S.L., Murali, R., Burnett, R.M., The crystal structure of a Fab fragment to the melanoma-associated GD2 ganglioside. J Struct Biol 119 (1997), 6–16.
37. 37 Agostino, M., Yuriev, E., Ramsland, P.A., Antibody recognition of cancer-related gangliosides and their mimics investigated using in silico site mapping. PLoS One, 7, 2012, e35457.
38. 38 Kaminski, M.J., MacKenzie, C.R., Mooibroek, M.J., Dahms, T.E., Hirama, T., Houghton, A.N., Chapman, P.B., Evans, S.V., The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces. Demonstration of an intermolecular beta-sheet interaction between VH domains. J Biol Chem 274 (1999), 5597–5604.
39. 39 Krengel, U., Olsson, L.L., Martinez, C., Talavera, A., Rojas, G., Mier, E., Angstrom, J., Moreno, E., Structure and molecular interactions of a unique antitumor antibody specific for N-glycolyl GM3. J Biol Chem 279 (2004), 5597–5603.
40. 40 Talavera, A., Eriksson, A., Okvist, M., Lopez-Requena, A., Fernandez-Marrero, Y., Perez, R., Moreno, E., Krengel, U., Crystal structure of an anti-ganglioside antibody, and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody. Mol Immunol 46 (2009), 3466–3475.
41. 41 Sonnino, S., Mauri, L., Chigorno, V., Prinetti, A., Gangliosides as components of lipid membrane domains. Glycobiology 17 (2007), 1R–13R.
42. 42•• Koldso, H., Shorthouse, D., Helie, J., Sansom, M.S., Lipid clustering correlates with membrane curvature as revealed by molecular simulations of complex lipid bilayers. PLoS Comput Biol, 10, 2014, e1003911 Excellent theoretical study of the complex nature of biological membranes. Using molecular dynamics, the structure of a multicomponent lipid bilayer was simulated and among other observations it showed how gangliosides spontaneously cluster and are associated with regions of membrane curvature.
43. 43• Aigal, S., Claudinon, J., Romer, W., Plasma membrane reorganization: a glycolipid gateway for microbes. Biochim Biophys Acta 1853 (2015), 858–871 Comprehensive review of the structural and molecular mechanisms for membrane reorganization, uptake and invasion mediated by pathogens and toxins. A major topic covered is the membrane protrusions and indentations that are associated with clustering of gangliosides, which may be of relevance to the direct membrane effects of many glycolipid-binding antibodies.
44. 44 Ido, S., Kimiya, H., Kobayashi, K., Kominami, H., Matsushige, K., Yamada, H., Immunoactive two-dimensional self-assembly of monoclonal antibodies in aqueous solution revealed by atomic force microscopy. Nat Mater 13 (2014), 264–270.
45. 45 Sheriff, S., Chang, C.Y., Jeffrey, P.D., Bajorath, J., X-ray structure of the uncomplexed anti-tumor antibody BR96 and comparison with its antigen-bound form. J Mol Biol 259 (1996), 938–946.
46. 46 Farrugia, W., Scott, A.M., Ramsland, P.A., A possible role for metallic ions in the carbohydrate cluster recognition displayed by a Lewis Y specific antibody. PLoS One, 4, 2009, e7777.
47. 47 de Geus, D.C., van Roon, A.M., Thomassen, E.A., Hokke, C.H., Deelder, A.M., Abrahams, J.P., Characterization of a diagnostic Fab fragment binding trimeric Lewis X. Proteins 76 (2009), 439–447.
48. 48 Salentin, S., Schreiber, S., Haupt, V.J., Adasme, M.F., Schroeder, M., PLIP: fully automated protein–ligand interaction profiler. Nucleic Acids Res 43 (2015), W443–W447.
49. 49 Lefranc, M.P., Giudicelli, V., Duroux, P., Jabado-Michaloud, J., Folch, G., Aouinti, S., Carillon, E., Duvergey, H., Houles, A., Paysan-Lafosse, T., et al. IMGT(R), the international ImMunoGeneTics information system(R) 25 years on. Nucleic Acids Res 43 (2015), D413–D422.